OCT4, 84.6% ± 6.6% for SOX2, 84.4 ± 2.9% for KLF4, and 90.8% ± 6.4% for cMYC; 82.4% ± 1.7% of the cells co-expressed OCT4 and KLF4. Based upon these observed efficiencies for expression of the single factors and for OCT4 and KLF4 co-expression, we can calculate an estimated minimal percentage of cells co-expressing all four factors as 43.1%, and an estimated maximal percentage of cells co-expressing all four factors as 84.1% (minimal percentage = SOX2% + cMyc% + OCT4/KLF4% -200; maximal percentage = min(SOX2%, cMYC%, OCT4/KLF4%)). e-h, Nkx3.1, Foxa1, and AR are not detected by immunostaining in MEFs (e,f) or iEpt cells (g,h) . i-k, iEpt cells infected with lentiviruses expressing all three MRs (Nkx3.1, Representative data are shown from 2 independent experiments. Predicted additive effects were estimated using a log-linear model based upon observed efficiencies of prostate tissue formation in the reprogramming assay. Comparison of the predicted additive effects to the observed (synergistic) effect was performed using a one-sample t-test. Expression of exogenous MRs and pluripotency factors was determined from average read counts based on RNA-seq data (see Methods) for the untranslated regions (UTRs) and coding regions. For exogenous mouse MRs (Nkx3.1 and Foxa1), the ratio of average read counts between 3' UTR and coding region is shown, with a higher ratio indicating the presence of endogenous transcripts, and a lower ratio indicating the presence of exogenous transcripts (that lack UTRs). For exogenous human AR and pluripotency factors (OSKM), which lack UTRs, the average read counts for the coding regions are shown, indicating the presence or absence of these transcripts. Read counts for six independent prostate samples were averaged and used for comparison.
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